Chemed Reports Fourth-Quarter 2020 Results.

Q4 ADJUSTED EARNINGS PER SHARE $5.13.
Q4 GAAP EARNINGS PER SHARE $6.96.
Q4 REVENUE $533 MILLION VERSUS REFINITIV IBES ESTIMATE OF $537.2 MILLION.
SEES FY 2021 ADJUSTED EARNINGS PER SHARE $17.00 TO $17.50 EXCLUDING ITEMS.Q4 EARNINGS PER SHARE ESTIMATE $5.13 -- REFINITIV IBES DATA.
QTRLY  VITAS NET PATIENT REVENUE OF $332 MILLION, DECLINE OF 2.3%.
QTRLY  ROTO-ROOTER REVENUE OF $201 MILLION, AN INCREASE OF 10.2%.
VITAS ANTICIPATES CONTINUED WEAK OCCUPANCY AND CORRESPONDING WEAK REFERRALS FROM SENIOR HOUSING FOR FIRST HALF OF 2021.
ANTICIPATES SENIOR HOUSING OCCUPANCY WILL BEGIN TO NORMALIZE TO PRE-PANDEMIC OCCUPANCY STARTING IN SECOND HALF OF CALENDAR YEAR 2021.
VITAS 2021 REVENUE IS ESTIMATED TO DECLINE APPROXIMATELY 4.0%.
ROTO-ROOTER IS FORECASTED TO ACHIEVE FULL-YEAR 2021 REVENUE GROWTH OF 5% TO 6%.
FULL-YEAR 2021 ADJUSTED EARNINGS PER DILUTED SHARE IS ESTIMATED TO BE IN RANGE OF $17.00 TO $17.50.